More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.58B
EPS
-1.26
P/E ratio
--
Price to sales
6.54
Dividend yield
--
Beta
1.696443
Previous close
$9.58
Today's open
$9.58
Day's range
$9.03 - $9.75
52 week range
$5.32 - $14.38
show more
CEO
Marianne De Backer
Employees
367
Headquarters
San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
171270773
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Vir Biotechnology Announces Proposed Public Offering
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares.
Business Wire • Nov 12, 2026

Vir Biotechnology Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, be.
Business Wire • Nov 13, 2026

Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undetectable virus at 48 weeks.
MarketBeat • Nov 10, 2026

Vir Biotechnology: Fairly Valued After Phase 3 Success?
Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable virus rates, with a strong safety profile and no discontinuations. With $991.3 million in cash, a $5.79 per-share cash floor, and funding secured into H2 2028, downside risk is limited.
Seeking Alpha • Nov 10, 2026

Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment
Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.
Investors Business Daily • Nov 9, 2026

Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript
Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO & Director Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Philip Nadeau - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Cynthia Garcia Joseph Stringer - Needham & Company, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Presentation Operator Hello, and welcome to Vir Biotechnology's ECLIPSE 1 Pivotal Phase 3 Topline Results and SOLSTICE Finite Treatment Conference Call. As a reminder, this call is being recorded.
Seeking Alpha • Nov 9, 2026

Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Nov 9, 2026

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). Topline results were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “For people living with CHD, the goal is not simply to reduce.
Business Wire • Nov 8, 2026

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). These data include new analyses presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “We are seeing rapid viral suppression that deepens over time, alon.
Business Wire • Nov 8, 2026

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call
Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vir Biotechnology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.